Condition

Adaptive Radiotherapy

ClinicalTrials.gov condition label

Clinical trials6

Recruiting4

Common interventions9

Lead sponsors shown6

Clinical trials

6 shown

Ultrahypofractionated, Adaptive Radiation Therapy of Prostate CancerNCT06355050 · 2026-04-01

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer PatientsNCT07138755 · 2025-08-29

Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary OligometastasesNCT06542159 · 2024-05-22

MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)NCT05183074 · 2021-02-01

Response With Interim PSMA PET in Metastatic Castration-sensitive Prostate Cancer for Optimization of Adaptive Metastasis-directed Radiotherapy DeliveryNCT07674771 · 2026-10-01

NOT_YET_RECRUITING

Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung CancerNCT07259447 · 2024-06-21

ACTIVE_NOT_RECRUITING

Common interventions

68Ga-PSMA-11DRUG1 Adaptive stereotactic ablative radiotherapy (SABR)RADIATION1 Adaptive stereotactive ablative radiotherapy (SABR)RADIATION1 CBCT-based adaptive radiotherapyDEVICE1 Conventional SBRTRADIATION1 Drug: 68-Ga PSMA11DRUG1 ExperimentalDRUG1 MR-linacDEVICE1 Online adaptive SBRTRADIATION1

Leading sponsors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences1 Jena University Hospital1 Sun Yat-sen University1 The Third Xiangya Hospital of Central South University1 Universitaire Ziekenhuizen KU Leuven1 University of Texas Southwestern Medical Center1

Trial status mix

RECRUITING4

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

NA2

PHASE22

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.